Statement: the primary trial recorded one patient with congestive Cardiac failure, the secondary trial recorded more.
Primary_evidence: Adverse Events 1:   Total: 8/30 (26.67%)   Heart Failure 1/30 (3.33%)   Vertigo 1/30 (3.33%)   Small intestinal obstruction 1/30 (3.33%)   Fever 1/30 (3.33%)   Aspartate aminotransferase increased 1/30 (3.33%)   Alanine aminotransferase increased 1/30 (3.33%)   Back Pain 1/30 (3.33%)   Pleural effusion 1/30 (3.33%)   Rash maculo-papular 1/30 (3.33%)   Hypotension 1/30 (3.33%)
Secondary_evidence: Adverse Events 1:   Total: 2/3 (66.67%)   Febrile neutropenia 1/3 (33.33%)   Atrial flutter 0/3 (0.00%)   Atrial fibrillation 0/3 (0.00%)   Cardiac failure 0/3 (0.00%)   Sinus bradycardia 1/3 (33.33%)   Supraventricular tachycardia 0/3 (0.00%)   Abdominal pain upper 0/3 (0.00%)   Dysphagia 0/3 (0.00%)   Intestinal mass 0/3 (0.00%)   Pancreatitis acute 0/3 (0.00%)   Small intestinal obstruction 0/3 (0.00%) Adverse Events 2:   Total: 0/3 (0.00%)   Febrile neutropenia 0/3 (0.00%)   Atrial flutter 0/3 (0.00%)   Atrial fibrillation 0/3 (0.00%)   Cardiac failure 0/3 (0.00%)   Sinus bradycardia 0/3 (0.00%)   Supraventricular tachycardia 0/3 (0.00%)   Abdominal pain upper 0/3 (0.00%)   Dysphagia 0/3 (0.00%)   Intestinal mass 0/3 (0.00%)   Pancreatitis acute 0/3 (0.00%)   Small intestinal obstruction 0/3 (0.00%)